Skip to content
10-K

Annual Report

Relmada Therapeutics, Inc. RLMD

0001213900-26-031862

← back to feed
Filed
Mar 19, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Mar 16, 2026 104.89M sh
Shares Diluted FY 2025 · Dec 31, 2025 39.48M sh
Shares Diluted FY 2025 · Dec 31, 2024 30.16M sh
Operating Cash Flow FY 2025 · Dec 31, 2025 −$45.79M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$51.76M
Short Term Investments FY 2025 · Dec 31, 2025 $89.51M
Short Term Investments FY 2025 · Dec 31, 2024 $41.05M
Cash And Equivalents FY 2025 · Dec 31, 2025 $3.5M
Cash And Equivalents FY 2025 · Dec 31, 2024 $3.86M
Stockholders Equity FY 2025 · Dec 31, 2025 $86.51M
Stockholders Equity FY 2025 · Dec 31, 2024 $35.52M
Stockholders Equity FY 2025 · Dec 31, 2023 $85.36M
Current Liabilities FY 2025 · Dec 31, 2025 $6.43M
Current Liabilities FY 2025 · Dec 31, 2024 $10.29M
Total Liabilities FY 2025 · Dec 31, 2025 $7.49M
Total Liabilities FY 2025 · Dec 31, 2024 $10.3M
Current Assets FY 2025 · Dec 31, 2025 $93.98M
Current Assets FY 2025 · Dec 31, 2024 $45.8M
Total Assets FY 2025 · Dec 31, 2025 $94M
Total Assets FY 2025 · Dec 31, 2024 $45.82M
Eps Diluted FY 2025 · Dec 31, 2025 −$1.45
Eps Diluted FY 2025 · Dec 31, 2024 −$2.65
Eps Basic FY 2025 · Dec 31, 2025 −$1.45
Eps Basic FY 2025 · Dec 31, 2024 −$2.65
Sga Expense FY 2025 · Dec 31, 2025 $32.22M
Sga Expense FY 2025 · Dec 31, 2024 $37.72M
Rd Expense FY 2025 · Dec 31, 2025 $26.88M
Rd Expense FY 2025 · Dec 31, 2024 $46.18M
Net Income FY 2025 · Dec 31, 2025 −$57.39M
Net Income FY 2025 · Dec 31, 2024 −$79.98M
Operating Income FY 2025 · Dec 31, 2025 −$59.1M
Operating Income FY 2025 · Dec 31, 2024 −$83.89M